Home › Research › Treatments
Therapeutic evaluation of solid lipid nanoparticle of quercetin in pentylenetetrazole induced cognitive impairment of zebrafish
Rishitha N, Muthuraman A.. Life sciences, 2018-03-06
Topic: Brain proteins, microglia and lab models
Plain-language summary
Background Quercetin is a major flavonoid in various plants. It possesses the multiple pharmacological actions like vascular integrity and regulatory action of the blood-brain barrier. Aims The present study is focused on evaluating the role of solid lipid nanoparticle of quercetin in pentylenetetrazole (PTZ) induced cognitive impairment of Danio rerio species. Main methods The memory impairment of zebrafish was induced by exposing of PTZ in 7.5 mM solution. The pretreatment of solid lipid nanoparticle of quercetin (SLN-Q; 5 and 10 mg/kg) was administered by single intraperitoneal (i.p.) injection. The reference control i.e., donepezil (10 mg/kg) was administered by single intraperitoneal (i.p.) injection. The learning and memory levels were evaluated with different tests like light and dark chamber test; partition preference test; and three (horizontal) compartment tests. In addition, the PTZ induced biochemical changes such as acetylcholinesterase activity, lipid peroxidation, and reduced glutathione levels were assessed in the brain of zebrafish. Key findings The solid lipid nanoparticle of quercetin found to possess the attenuating effect in PTZ induced neurocognitive impairments along with amelioration of biochemical changes. This effect is similar to that of donepezil pretreated group. Significance Therefore, this solid lipid nanoparticle of quercetin can be used as future nanomedicine for various neurodegenerative disorders like Alzheimer and Parkinson disorders due to its potential anti-oxidative, anti-lipid peroxidative and acetylcholinesterase inhibitory actions.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Rishitha, N., & Muthuraman, A. (2018). Therapeutic evaluation of solid lipid nanoparticle of quercetin in pentylenetetrazole induced cognitive impairment of zebrafish. Life sciences. https://doi.org/10.1016/j.lfs.2018.03.010
Vancouver
Rishitha N, Muthuraman A. Therapeutic evaluation of solid lipid nanoparticle of quercetin in pentylenetetrazole induced cognitive impairment of zebrafish. Life sciences. 2018. doi:10.1016/j.lfs.2018.03.010. PMID: 29522770.
BibTeX
@article{rishitha2018-29522770,
author = {Rishitha, N. and Muthuraman, A.},
title = {{Therapeutic evaluation of solid lipid nanoparticle of quercetin in pentylenetetrazole induced cognitive impairment of zebrafish}},
journal = {Life sciences},
year = {2018},
doi = {10.1016/j.lfs.2018.03.010},
pmid = {29522770},
url = {https://doi.org/10.1016/j.lfs.2018.03.010}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- The learning and memory levels were evaluated with different tests like light and dark chamber test; partition preference test; and three (horizontal) compartment tests.
- In addition, the PTZ induced biochemical changes such as acetylcholinesterase activity, lipid peroxidation, and reduced glutathione levels were assessed in the brain of zebrafish.
- Key findings The solid lipid nanoparticle of quercetin found to possess the attenuating effect in PTZ induced neurocognitive impairments along with amelioration of biochemical changes.
- This effect is similar to that of donepezil pretreated group.
- Significance Therefore, this solid lipid nanoparticle of quercetin can be used as future nanomedicine for various neurodegenerative disorders like Alzheimer and Parkinson disorders due to its potential anti-oxidative, anti-lipid peroxidative and acetylcholinesterase inhibitory actions.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 38/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 22 of the 58 points we could judge it on, which is 38 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Life sciences) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2018 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Laboratory or animal study (title names “zebrafish”) — scores zero |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 29522770) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 22 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 22 of the 58 points we could judge it on is 38 out of 100. |
| Total | 38 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.